Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

27 Mar 2014
by Working Group

Posted in Announcements, TB News, TB Pediatrics, Uncategorized

TB Alliance makes series of announcements regarding new initiatives to combat childhood TB

TBAlliance

TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

Sirturo

The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.

26 Nov 2013

EMA Reverses Opinion on Delamanid for MDR-TB

otsuka

A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.

6 Sep 2013
by Working Group

Posted in Announcements, Events

2013 WORKING GROUP ON NEW TB DRUGS ANNUAL MEETING IN PARIS, FRANCE ON OCTOBER 29TH

annual 2013

You are invited to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2013 in Paris, France on Oct. 29th. Agenda included.

28 Aug 2013
by Working Group

Posted in Announcements, Events, TB Drug Development

6th International Workshop on Clinical Pharmacology of Tuberculosis Drugs September 9, 2013 in Denver, CO.

tb-e1332174457196

This interactive workshop is held in conjunction with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  The workshop is intended to provide clinicians, researchers, students and representatives from regulatory non-government organizations active in the TB-field with a platform for presentation and discussion of the latest scientific developments in the field.  The workshop will allow [...]

30 Jul 2013

EMA fails to recommend Otsuka’s Delamanid for MDR TB

otsuka

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) failed to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB). A letter from the Treatment Action Group criticizing this decision is included.

17 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Sequella Acquires Exclusive Worldwide Rights to Pfizer’s Sutezolid

PNU100480

Sequella today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).

9 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Otsuka Begins Paediatric MDR-TB Trials

otsuka

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.

24 Jun 2013
by Working Group

Posted in Announcements, Early Drug Development, Events

“Targets for Tomorrow” Workshop at GRC in Italy July 2013

tb-review-4.10-lipsitch-feature

We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort, Lucca (Barga), Italy.

13 Jun 2013

WHO Issues Interim Guidance on the Use of Bedaquiline to Treat

who-logo

The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB).